BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/19/2025 6:12:08 AM | Browse: 161 | Download: 604
 |
Received |
|
2024-09-06 21:54 |
|
Peer-Review Started |
|
2024-09-06 21:54 |
|
First Decision by Editorial Office Director |
|
2025-01-16 00:27 |
|
Return for Revision |
|
2025-01-16 00:27 |
|
Revised |
|
2025-02-09 15:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-02-17 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-17 07:30 |
|
Articles in Press |
|
2025-02-17 07:30 |
|
Edit the Manuscript by Language Editor |
|
2025-02-22 19:53 |
|
Typeset the Manuscript |
|
2025-03-03 10:41 |
|
Publish the Manuscript Online |
|
2025-03-19 06:12 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Editorial |
| Article Title |
Treatment of immunoglobulin A nephropathy: A current perspective and future prospects
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yusuf Ziya Şener and Seher Şener |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yusuf Ziya Şener, MD, Department of Cardiology, Thoraxcentrum, Erasmus MC, Beypazarı, Rotterdam 3015 GD, Netherlands. yzsener@yahoo.com.tr |
| Key Words |
Immunoglobulin A nephropathy; Telitacicept; Complement inhibitors; B-cell lineage depletion; Anti-proteinuric treatment |
| Core Tip |
Immunoglobulin A nephropathy represents the most prevalent form of primary glomerulonephritis, with the potential for progression to end-stage renal disease. Lifestyle modifications, dietary alterations and anti-proteinuric pharmacological agents have been demonstrated to induce clinical remission in the majority of cases. However, some cases do not respond the supportive therapy. Short term of corticosteroids should be considered in unresponsive cases. However, novel therapeutic strategies are required for patients with steroid-refractory disease. B-cell lineage depletion therapies and complement system inhibitors represent promising avenues for future research and may be considered in cases of persistent disease despite guideline-directed medical treatment. |
| Publish Date |
2025-03-19 06:12 |
| Citation |
Şener YZ, Şener S. Treatment of immunoglobulin A nephropathy: A current perspective and future prospects. World J Clin Cases 2025; 13(19): 101196
|
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i19/101196.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i19.101196 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
